company background image
SESN

Sesen Bio NasdaqCM:SESN Stock Report

Last Price

US$0.61

Market Cap

US$123.7m

7D

-2.8%

1Y

-16.7%

Updated

31 Jan, 2023

Data

Company Financials +

SESN Stock Overview

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer.

SESN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Sesen Bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sesen Bio
Historical stock prices
Current Share PriceUS$0.61
52 Week HighUS$0.96
52 Week LowUS$0.36
Beta0.86
1 Month Change0.082%
3 Month Change11.87%
1 Year Change-16.68%
3 Year Change-32.97%
5 Year Change-28.74%
Change since IPO-94.38%

Recent News & Updates

Recent updates

We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

Apr 17
We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

Dec 05
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Aug 12
Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Feb 18
News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Jan 26
Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

Dec 21
Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

Shareholder Returns

SESNUS BiotechsUS Market
7D-2.8%0.8%2.8%
1Y-16.7%7.1%-9.2%

Return vs Industry: SESN underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: SESN underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is SESN's price volatile compared to industry and market?
SESN volatility
SESN Average Weekly Movement7.3%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: SESN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: SESN's weekly volatility has decreased from 14% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200817Thomas Cannellhttps://sesenbio.com

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent.

Sesen Bio, Inc. Fundamentals Summary

How do Sesen Bio's earnings and revenue compare to its market cap?
SESN fundamental statistics
Market CapUS$123.68m
Earnings (TTM)-US$3.37m
Revenue (TTM)US$60.00m

2.1x

P/S Ratio

-36.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SESN income statement (TTM)
RevenueUS$60.00m
Cost of RevenueUS$25.31m
Gross ProfitUS$34.69m
Other ExpensesUS$38.05m
Earnings-US$3.37m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.017
Gross Margin57.81%
Net Profit Margin-5.61%
Debt/Equity Ratio0%

How did SESN perform over the long term?

See historical performance and comparison